Clinical Trials Logo

Lung Cancer Stage II clinical trials

View clinical trials related to Lung Cancer Stage II.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05281237 Recruiting - Lung Cancer Clinical Trials

Avecure Flexible Microwave Ablation Probe For Lung Nodules

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)

NCT ID: NCT05258448 Recruiting - Cardiac Disease Clinical Trials

COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)

COLA
Start date: August 2015
Phase:
Study type: Observational [Patient Registry]

Patients with loco-regional NSCLC planned for curative treatment with chemoradiotherapy will be invited to participate in a prospective study; besides routine treatment, the patients will be followed with an ECG and cardiac MR for at least two years after radiotherapy treatment.

NCT ID: NCT04991025 Recruiting - Lung Cancer Clinical Trials

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Start date: October 19, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy more effective in shrinking the cancer. This study will examine whether adding certolizumab to the usual treatment approach is better than, the same as, or worse than the usual approach alone.

NCT ID: NCT03290534 Recruiting - Lung Cancer Clinical Trials

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

Start date: March 13, 2019
Phase: Phase 2
Study type: Interventional

This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.